Keywords
Microbiología
Virología parvovirus B-19 humano
Virus Infectious diseases
Microbiology
Virology
Human parvovirus B19
Viruses
How to Cite
Abstract
Since its casual discovery and the role as human pathogen related to transient aplastic crisis, infectious eritema, human parvovirus B19 has been associated with a broad spectrum of nosological entities, each one with specific manifestations with clinical and epidemiological relevance. The above statment has encouraged modern medicine to study human parvovirus B19 structures, characteristics deeply, transmission ways as well the immunologic behaviour when an active infection is faced. Currently there is no specific treatment and only under especial conditions gammaglobulin is recommended. This paper shows an updated - 2011 review regard to the main aspects of parvovirus B19.
References
Cossart YE, Field AM, Cant B, Widdows D, Parvoviruslike particles in human sera. Lancet 1975; 1:72. https://doi.org/10.1016/S0140-6736(75)91074-0
Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483. https://doi.org/10.1128/JCM.37.8.2483-2487.1999
Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987; 6:711. https://doi.org/10.1097/00006454-198708000-00003
Kelly HA, Siebert D, Hammond R, Leydon J. The agespecific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 2000; 124:449-457. https://doi.org/10.1017/S0950268899003817
Yamashita K, Matsunaga Y, Taylor-Wiedeman J, Yamazaki S. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn J Med Sci Biol 1992; 45:49. https://doi.org/10.7883/yoken1952.45.49
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151. https://doi.org/10.1099/00222615-25-2-151
Public Health Laboratory Service Working Party on Fifth Disease. 1990. Prospective study of human parvovirus (B19) infection in pregnancy. Br Med J 300:1166-1170. https://doi.org/10.1136/bmj.300.6733.1166
Azzi A, Morfini M, Mannucci PM. The transfusion associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204. https://doi.org/10.1016/S0887-7963(99)80033-9
Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine: summary of a workshop. Transfusion 2001; 41:130-5. https://doi.org/10.1046/j.1537-2995.2001.41010130.x
Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061. https://doi.org/10.1001/jama.1990.03440150069028
Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37. https://doi.org/10.1016/S0002-9378(96)70370-8
Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75:97. https://doi.org/10.1046/j.1423-0410.1998.7520097.x
Parrish CR. Pathogenesis of feline panleukopenia virus and canine parvovirus. Baillieres Clin Haematol 1995; 8:57-71. https://doi.org/10.1016/S0950-3536(05)80232-X
Berns K. Parvoviridae: the viruses and their replication, Fields virology Lippincott-Raven, Philadelphia, Pa. 1996 p. 2173-97.
International Committee on Taxonomy of Viruses. 2000. Virus taxonomy: classification and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses. Springer-Verlag, Vienna, Austria.
Berns KI, Bohenzky RA. Adeno-associated viruses: an update. Adv. Virus Res.1987; 32:243-306. https://doi.org/10.1016/S0065-3527(08)60479-0
Deiss V, Tratschin JD, M Weitz, Siegl G. Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini. Virology 1990; 175:247-254. https://doi.org/10.1016/0042-6822(90)90205-6
Moffatt S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70:8485. https://doi.org/10.1128/JVI.70.12.8485-8491.1996
Kaufmann B, Simpson, AA, Rossmann, MG. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. USA 2004; 101:11628. https://doi.org/10.1073/pnas.0402992101
Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 1993; 262:114. https://doi.org/10.1126/science.8211117
Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192. https://doi.org/10.1056/NEJM199404283301704
Ozawa K, Ayub J, Kajigaya S, Shimada T, Young NS. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62:2884-9. https://doi.org/10.1128/JVI.62.8.2884-2889.1988
Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72:3018-28. https://doi.org/10.1128/JVI.72.4.3018-3028.1998
Kaufmann B, Baxa U, Chipman, PR, et al. Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology 2005; 332:189. https://doi.org/10.1016/j.virol.2004.11.037
Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586. https://doi.org/10.1056/NEJMra030840
Norbeck O, Isa A, Pohlmann C, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117. https://doi.org/10.1128/JVI.79.18.12117-12121.2005
Von Poblotzki A, Gerdes C, Reischl U, et al. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70:7327. https://doi.org/10.1128/JVI.70.10.7327-7330.1996
Serjeant BE, Hambleton RR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358:1779- 80. https://doi.org/10.1016/S0140-6736(01)06807-6
Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411. https://doi.org/10.1182/blood.V67.5.1411.1411
Wagner AD, Goronzy JJ, Matteson EL, Weyand CM. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995; 70:261. https://doi.org/10.4065/70.3.261
Heegaard ED, Brown KE, Human Parvovirus B19. Clin Microbiol Rev 2002;15: 485-505. https://doi.org/10.1128/CMR.15.3.485-505.2002
Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166. https://doi.org/10.1136/bmj.300.6733.1166
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA. Clinical manifestations of human parvovirus B19 in adults. Arch. Intern. Med. 1989; 149:1153-56. https://doi.org/10.1001/archinte.149.5.1153
Zerbini M, Musiani M, Venturoli S, Gallinella G, Gibellini D, Gentilomi G, et al. Different syndromes associated with B19 parvovirus viraemia in paediatric patients: report of four cases. Eur. J. Pediatr. 1992;151:815-817. https://doi.org/10.1007/BF01957931
Heegaard ED, Taaning EB. Parvovirus B19 and parvovirus V9 are not associated with Henoch-Schonlein purpura in children. Pediatr Infect Dis J 2002; 21:31. https://doi.org/10.1097/00006454-200201000-00007
Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257. https://doi.org/10.1093/infdis/152.2.257
Woolf AD, Campion GV, Chishick, A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153. https://doi.org/10.1001/archinte.1989.00390050111022
Schwarz TF, Wiersbitzky S, Pambor M. Case report: Detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43:171. https://doi.org/10.1002/jmv.1890430214
Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 2000; 27:2444.
Oguz F, Akdeniz C, Unuvar E, et al. Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J Paediatr Child Health 2002; 38:358. https://doi.org/10.1046/j.1440-1754.2002.00789.x
Soderlund M, Von Essen R, Haapasarri J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063. https://doi.org/10.1016/S0140-6736(96)09110-6
Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53:459. https://doi.org/10.1099/jmm.0.05485-0
Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:8227. https://doi.org/10.1073/pnas.95.14.8227
Morgan-Capner, P, Crowcroft, NS. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health 2002; 5:59.
Haan TR, Akker ES, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76. https://doi.org/10.1111/j.1471-0528.2007.01555.x
Kuhl U. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965. https://doi.org/10.1161/CIRCULATIONAHA.105.548156
Tschope C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879. https://doi.org/10.1161/01.CIR.0000155615.68924.B3
Donoso Mantke O, Nitsche A, Meyer R, et al. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 2004; 31:32. https://doi.org/10.1016/j.jcv.2003.12.013
Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotizing vasculitis: Opportunistic infection or aetiological agent? Lancet 1994; 1:1255. https://doi.org/10.1016/S0140-6736(94)92152-0
Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci 2006; 51:1712. https://doi.org/10.1007/s10620-005-9061-5
Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia colibased VP1 EIA for detection of human parvovirus B19 immunoglobulin IgM and immunoglobulin IgG in sera of pregnant women. J Clin Microbiol 2000; 38:1472. https://doi.org/10.1128/JCM.38.4.1472-1475.2000
Kerr S, O'Keeffe G, Kilty, C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179. https://doi.org/10.1002/(SICI)1096-9071(199902)57:2<179::AID-JMV16>3.0.CO;2-T
Erdman DD. Human parvovirus B19: Laboratory diagnosis. In: Monographs in Virology: Human Parvovirus B19, Anderson, LJ, Young, NS (Eds), Karger, New York 1997. p. 93. https://doi.org/10.1159/000061678
Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia colibased VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J Clin Microbiol 2000; 38:1472. https://doi.org/10.1128/JCM.38.4.1472-1475.2000
Butchko AR, Jordan JA. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. J Clin Microbiol 2004; 42:3191. https://doi.org/10.1128/JCM.42.7.3191-3195.2004
Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061. https://doi.org/10.1001/jama.1990.03440150069028
Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675. https://doi.org/10.1086/368382
ClinicalTrials.gov. B-19 parvovirus vaccine study by clinical trials. Disponible en http://clinicaltrials.gov/ct2/show/NCT00379938 (Evaluado el 20 de Octubre de 2010) Fecha de consulta: Septiembre 2010.
Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP, Impaired Gamma Interferon Responses against Parvovirus B19 by Recently Infected Children, J. Virol, 2000; 74 (21), 9903-9910. https://doi.org/10.1128/JVI.74.21.9903-9910.2000